Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer.

Publication — IRIC

Distinguishing lung adenocarcinoma (ADC) from squamous cell carcinoma (SCC) has a tremendous therapeutic implication. Sometimes, the commonly used immunohistochemistry (IHC) markers fail to discriminate between them, urging for the identification of new diagnostic biomarkers.

Date de publication: 1^st August 2018
Chercheur(euse)s: El-Khoury V, Béland M, Schritz A, Kim SY, Nazarov PV, Gaboury L, Sertamo K, Bernardin F, Batutu R, Antunes L, Bennett CW, Faÿs F, Berchem G, Kim YJ
Référence PubMed: Br. J. Cancer 2018;119(5):580-590
ID PubMed: 30078843
Affiliation: Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, 1 A-B Rue Thomas Edison, L-1445, Strassen, Luxembourg. victoria.elkhoury@lih.lu.